Home › Research › Getting a diagnosis
FDA approval of the Lumipulse G pTau217/β-amyloid 1-42 plasma ratio test: a new era in accessible Alzheimer's diagnosis
Biruk D. Ayalew, Zemichael G. Alemayehu, Tsimona D. Bonger, Brook L. Sime, Yonatan A. Zewdie, Yeamlak T. Tewodros, Sher Bano. Annals of Medicine and Surgery, 2025-12-17
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This review article discusses the FDA's May 2025 clearance of Fujirebio's Lumipulse G blood test, the first FDA-cleared blood test for aiding Alzheimer's diagnosis (via the pTau217/beta-amyloid 1-42 ratio). It explains that the test correctly ruled in amyloid pathology in roughly 90%+ of positive cases and correctly ruled it out in about 97% of negative cases, while noting real limits: it is only approved for symptomatic adults 55+ in specialized-care settings, hasn't been well validated across diverse racial/ethnic groups, and cannot be used to screen people without symptoms or to distinguish Alzheimer's from other brain diseases.
What this study adds
Evidence grade: Moderate
The FDA cleared the Lumipulse G blood test in May 2025 to help diagnose Alzheimer's in symptomatic adults 55 and older in specialized care, correctly ruling in amyloid pathology in over 90% of positive cases and ruling it out in about 97% of negative cases. Reported effect size: Reported FDA-decision performance: positive concordance >90%; negative concordance ~97.3%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ayalew, B. D., Alemayehu, Z. G., Bonger, T. D., Sime, B. L., Zewdie, Y. A., Tewodros, Y. T., et al. (2025). FDA approval of the Lumipulse G pTau217/β-amyloid 1-42 plasma ratio test: a new era in accessible Alzheimer's diagnosis. Annals of Medicine and Surgery.
Vancouver
Ayalew BD, Alemayehu ZG, Bonger TD, Sime BL, Zewdie YA, Tewodros YT, et al. FDA approval of the Lumipulse G pTau217/β-amyloid 1-42 plasma ratio test: a new era in accessible Alzheimer's diagnosis. Annals of Medicine and Surgery. 2025.
BibTeX
@article{ayalew2025-b441b009,
author = {Ayalew, Biruk D. and Alemayehu, Zemichael G. and Bonger, Tsimona D. and Sime, Brook L. and Zewdie, Yonatan A. and Tewodros, Yeamlak T. and Bano, Sher},
title = {{FDA approval of the Lumipulse G pTau217/β-amyloid 1-42 plasma ratio test: a new era in accessible Alzheimer's diagnosis}},
journal = {Annals of Medicine and Surgery},
year = {2025}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- FDA cleared the Lumipulse G pTau217/Abeta1-42 plasma ratio test on May 16, 2025 for symptomatic adults 55+
- Test correctly identified amyloid-positive cases in over 90% of instances and amyloid-negative cases in about 97.3%
- Restricted to specialized care settings; not validated for use in asymptomatic screening
- Authors flag gaps in validation across diverse ethnic/racial populations and need for cost-effectiveness data
Why it matters
The FDA cleared the Lumipulse G blood test in May 2025 to help diagnose Alzheimer's in symptomatic adults 55 and older in specialized care, correctly ruling in amyloid pathology in over 90% of positive cases and ruling it out in about 97% of negative cases. It is not approved for screening people without symptoms or for distinguishing Alzheimer's from other brain diseases, and it has not been well validated across diverse racial and ethnic groups.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Effect sizeReported FDA-decision performance: positive concordance >90%; negative concordance ~97.3%
- Evidence strengthModerate
Limitations
This is a narrative review of FDA approval data, not primary research with its own study population; the accuracy figures are as reported in the FDA decision summary, not independently re-verified by this paper's authors.
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people, randomized / blinded and indexed in PubMed because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 26 of the 62 points we could judge it on, which is 42 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Annals of Medicine and Surgery) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 0 / 2 | No PubMed ID and no DOI — scores zero (not stated in the record — scored 0) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 26 / 62 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 26 of the 62 points we could judge it on is 42 out of 100. |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Getting a diagnosis from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.